Overview

An Extension Study to Assess the Safety, Tolerability, and Effectiveness of the Long-Term Use of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Status:
Not yet recruiting

Trial end date:
2024-05-31

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to evaluate the safety and tolerability of the long-term use of TPIP in participants with PH-ILD from Study INS1009-211 (NCT05176951) and other lead-in studies of TPIP in participants with PH-ILD.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Insmed Incorporated

Treatments:

Treprostinil